Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560182 | 0.86 | EPHX2 (0.51) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL23573294 | 0.82 | EPHX2 (0.51) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL23011797 | 0.82 | EPHX2 (0.51) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL30884707 | 0.81 | EPHX2 (0.51) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL8341984 | 0.78 | EPHX2 (0.47) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL22916940 | 0.78 | EPHX2 (0.52) | EPHX2EPHX1NPY5RMEN1KMT2A | |
| SCHEMBL22432772 | 0.77 | EPHX2 (0.46) | EPHX2EPHX1NPY5RALDH1A1MEN1 | |
| SCHEMBL10311742 | 0.76 | KDM5A (0.50) | EPHX2EPHX1NPY5R | |
| SCHEMBL16368592 | 0.76 | ALDH1A1 (0.49) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL20665186 | 0.74 | HSD11B1 (0.50) | EPHX2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EPHX2 2834/4885EPHX1 2619/4885NPY5R 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.